Medisyn Technologies, Inc. Awarded Phase I SBIR Grant by Department of Defense to Discover and Develop Novel NSAIDs with Reduced GI Toxicity
1/25/2008 9:07:45 AM
MINNEAPOLIS--(BUSINESS WIRE)--Medisyn Technologies today announced that the company was recently awarded a Small Business Innovation Research (SBIR) Phase I grant from the Department of Defense (DoD) to discover and develop new non-steroidal anti-inflammatory drugs (NSAIDs) with reduced gastrointestinal toxicity. NSAIDs devoid of GI toxicity that may be potentially available without a prescription (over-the-counter) enables easier access for deployed military personnel.
comments powered by